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Background: Fanconi anemia (FA) is a genetic disease of birth defects, bone marrow failure, and cancer.
Results: FANCD2 and FANCJ bind and regulate each other’s chromatin localization.
Conclusion: Rather than FANCD2 being upstream of FANCJ, the two proteins interact in a coordinated set of actions depend-
ing on both proteins.
Significance: FA genes are mutated in many cancers, and five FA genes are familial breast cancer genes.
Fanconi anemia is a genetic disease resulting in bone marrow
failure, birth defects, and cancer that is thought to encompass a
defect in maintenance of genomic stability. Mutations in 16
genes (FANCA, B, C, D1, D2, E, F, G, I, J, L, M, N, O, P, and Q)
have been identified in patients, with the Fanconi anemia sub-
type J (FA-J) resulting from homozygous mutations in the
FANCJ gene. Here, we describe the direct interaction of
FANCD2 with FANCJ. We demonstrate the interaction of
FANCD2 and FANCJ in vivo and in vitro by immunoprecipita-
tion in crude cell lysates and from fractions after gel filtration
and with baculovirally expressed proteins. Mutation of the
monoubiquitination site of FANCD2 (K561R) preserves inter-
action with FANCJ constitutively in a manner that impedes
proper chromatin localizationof FANCJ. FANCJ is necessary for
FANCD2 chromatin loading and focus formation in response to
mitomycinCtreatment.Ourresults suggestnotonly thatFANCD2
regulates FANCJ chromatin localization but also that FANCJ is
necessary for efficient loading of FANCD2onto chromatin follow-
ing DNAdamage caused bymitomycin C treatment.
Fanconi anemia (FA)3 is a genetic disease, characterized by
chromosomal instability, bone marrow failure, congenital
defects, and cancer susceptibility (1) (2). The well documented
association of FA with DNA damage hypersensitivity has led
investigators to classify FA as a DNA repair defect disorder.
Sixteen FA genes have been identified: FANCA, B, C, D1, D2,
E, F, G, I, J, L, M, N, O, P, and Q, but only a few of their
sequences have yielded clues about their functions (3–8). Bio-
chemical studies of these proteins have shown that a “core com-
plex,” which includes FANCA, B, C, E, F, G, L, and M, is acti-
vated upon activation of the DNA damage response, typically
during the S phase (9–13). This complex translocates from the
cytoplasm to the nucleus, where it participates in the mono-
ubiquitination of FANCD2 (14, 15). Recent evidence suggests
that the FANCL subunit is the direct E3 ligase for FANCD2.
Shortly thereafter, monoubiquitinated FANCD2 is seen at
nuclear repair foci, along with BRCA1, RPA, PCNA, RAD51,
and others (16–19).
FA has been linked with the BRCA pathway, because
FANCD2 has been shown to interact with BRCA1 and BRCA2
(17, 20), and the familial breast cancer genesBRCA2 andPALB2
have been demonstrated to be the FA genes FANCD1 and
FANCN, respectively (21–23). The BRCA1-associated helicase,
BACH1/BRIP1, was identified as the gene encoding FANCJ
(24–27). A monoallelic missense mutation, R798X, leads to
familial breast cancer (28), whereas biallelic R798X leads to FA
in 80% of FA patients with the J subtype (FA-J) (26). Studies
have shown that cells from patients with FA-J exhibit normal
FANCD2 monoubiquitination, and it is hypothesized that the
function of FANCJ is downstream of this event in the FA path-
way (24–26). Although FANCJ is thought to be downstream of
FANCD2, it is not clear how FANCJ is regulated by FANCD2 in
the FApathway.A 2010 paper (29) in part noted co-localization of
FANCD2andFANCJanddependenceofFANCD2 foci formation
upon FANCJ. However, it did not assess interaction of the pro-
teins, didnot convincingly show foci formationeffects, anddidnot
show how each protein affects chromatin localization.
In this paper, we describe the interaction of nonubiquitinated
and ubiquitinated FANCD2 with FANCJ. We show by immuno-
precipitation, immunofluorescence microscopy and chromato-
graphic analysis of FA protein complexes that FANCJ-FANCD2
binding occurs primarily in the absence of inducedDNAdamage.
Mutation analysis shows that the FANCJ-FANCD2 interaction
is independent of a functional monoubiquitination site, dem-
onstrating that interaction is reduced upon monoubiquitina-
tion. Further, FANCJ and FANCD2 regulate each other’s
proper chromatin loading.
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EXPERIMENTAL PROCEDURES
Cell Culture—HeLa cells were cultured inDMEMcontaining
10% fetal bovine serum (Biowest, Miami, FL) and penicillin/
streptomycin (Invitrogen). EUFA0030 TERT fibroblasts (kindly
provided by H. Joenje) and EUFA0030 TERT FANCJ corrected
fibroblasts were cultured in RPMI (Invitrogen) with 20% fetal
bovine serum. FA-D2 mutant cells PD20, PD20 Flag-FANCD2
and FA-A mutant cells GM6914 and GM6914 Flag-FANCA
were cultured inDMEMcontaining 15% fetal bovine serumand
penicillin/streptomycin (30, 31).
Immunoprecipitation—HeLa cells, GM6914 FA-A mutant
cells corrected or not with pMMP-Flag-FANCA, and PD20
mutant FA-D2 cells transduced with pMMP-Flag-FANCD2
wild type or FANCD2(K561R) were cultured on 10 cm plates
and treated with or without 0.5 M mitomycin C (MMC) over-
night prior to harvest. Following PBS wash, 1 ml of the radioim-
mune precipitation assay buffer (150 mM NaCl, 1.0% Igepal
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris,
pH8.0)was added to cells. Extractswere cleared by centrifugation
at 13,000 rpm for 15 min at 4 °C. Supernatants were saved, and
equal amounts of extract were used for each immunoprecipita-
tion,with1gof antibody (FANCD2H-300,ornormal rabbit IgG;
Santa Cruz, Santa Cruz, CA) or 2 l of Brip1/FANCJ rabbit poly-
clonal antiserum (Novus Biologicals, Littleton, CO). Immunopre-
cipitations were then performed as previously described (30, 31).
Immunoblotting—Protein samples were suspended in SDS
loading buffer (50 mM Tris-Cl, pH 6.8, 2% SDS, 0.1% bromphe-
nol blue, 10% glycerol, 10% -mercaptoethanol) and boiled for
5 min. Because FANCJ and FANCD2 have similar molecular
masses (140 and 155 kDa, respectively), we split each sample for
immunoblot into two equal aliquots for blotting with either the
FANCJ or FANCD2antibodies. Sampleswere runon7.5%SDS-
polyacrylamide gel and transferred to nitrocellulosemembrane
(Bio-Rad). Membranes were blocked in TBS-T (TBS  0.1%
Tween 20) with 10% milk for 1.5 h and incubated in primary
antibody (FANCD2 H-300 1:1000 or BRIP1/FANCJ rabbit
polyclonal antibody 1:2000) for 1 h at room temperature in
TBS-T  1% milk. After washing, membranes were incubated
in secondary antibody (ECL anti-rabbit IgG, HRP; Amersham
Biosciences) 1:5000 in TBS-T 1% milk) for 1 h at room tem-
perature. Blots werewashed inTBS-T three times for 5min and
developed by chemiluminescence (Supersignal West Pico Kit
or Supersignal West Femto kit; Pierce). ImageJ software was
used to quantify bands on the blot.
In Vitro Immunoprecipitation—Recombinant FLAG-FANCJ
baculovirus, kindly provided by S. Cantor (25), was used to
infect High Five cells. The protein was isolated using anti-
FLAG M2 affinity gel (Sigma) as described (25) and further
purified in aMono S column (AmershamBiosciences). Recom-
binant Zz-tagged FANCD2 baculovirus, kindly provided by A.
D’Andrea (Dana-Farber Cancer Institute) (32), was used to
infect High Five cells. The protein was isolated using IgG-Sep-
harose beads and released from the beads using TEV protease.
FANCD2proteinwas further fractionated in aMonoQ column
(Amersham Biosciences). FANCD2 (2 g) was incubated with
FANCJ (2 g) in binding buffer (PBS, 1 mM DTT, and 0.01%
Igepal) for 30 min on ice. Then the mixture was incubated with
10 l of anti-Flag-agarose beads for 1 h at 4 °C with a rocking
block. The beads were pelleted by centrifugation, and the
supernatantwas saved. Afterwashing three timeswith 100l of
binding buffer, the beadswere treatedwith 20l of SDS loading
buffer to elute bound proteins. The supernatant (1 l), wash (1
l), and SDS eluate (1 l) were subjected to SDS-PAGE, and
protein contents were identified by immunoblot. Immunoblot
analysis (as opposed to gel staining) was used because of the
closely similar molecular mass of each protein.
Chromatography—FA-D2 PD20  pMMP-FlagFANCD2
cells were cultured on 15-cmplates. Following PBSwash, whole
cell extract was prepared by lysing cells in nondenaturing lysis
buffer (1% Triton X-100, 50 mM Tris-Cl, pH 7.4, 300 mMNaCl,
0.5 mM EDTA, 0.02% NaN3, 1 g/ml leupeptin, 1 g/ml pep-
statin, 1 g/ml aprotinin, 2 mM sodium pyrophosphate, 2 mM
sodium orthovanadate). Extracts were cleared by centrifuga-
tion at 14,000 rpm for 15 min at 4 °C. Supernatants were run
through a P11 column, and the flow through was loaded on a
Superose 6 gel filtration column (GE Healthcare). Fractions
were eluted in nondenaturing lysis buffer, collected, and ana-
lyzed by SDS-PAGE. Selected fractions were isolated and ana-
lyzed by immunoblot for FANCJ and FANCD2 fractionation.
The fractions containing FANCD2 and FANCJ were combined
and subjected to FANCD2 immunoprecipitation for FANCD2-
FANCJ interaction. Fraction sizes on column were standard-
ized using molecular mass standards (GE Healthcare).
ImmunofluorescenceMicroscopy—Cells were plated in 8-well
chamber slides and allowed to adhere 24–48 h and then treated
with 0.5 M MMC for 24 h. Slides were rinsed with PBS and
fixed with 4% paraformaldehyde for 5 min at room tempera-
ture. Slides were rinsed with PBS, and cells were permeabilized
with PBS containing 0.3% Triton X-100 for 5 min at room tem-
perature. After a final rinse with PBS, slides were blocked in
antibody/blocking buffer (PBS with 10% normal goat serum
(Invitrogen), 0.1% Nonidet P-40) for 30 min at room tempera-
ture. Slides were incubated with primary antibody, FANCD2
Fl17 mAb (Santa Cruz) or normal mouse IgG (Santa Cruz)
diluted 1:1000 in antibody buffer (PBS with 0.5% BSA and 0.1%
Nonidet P-40) overnight at 4 °C in a humidified chamber. After
washing three times for 5 min in wash buffer (PBS  0.1%
Tween 20), slides were incubated in secondary antibody, Cy3-
conjugated goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories,Westgrove, PA), diluted 1:1000 in antibody buffer
for 1 h at room temperature or Alexa 488-conjugated goat anti-
rabbit (Invitrogen) 1:1000 in antibody/blocking buffer for 45
min at room temperature. Slides were washed three times for 5
min inwash buffer and two times for 5min in PBS andmounted
with VectaShieldmountingmediumwith DAPIHard Set (Vec-
tor Laboratories, Burlingame, CA). Slides were analyzed on a
Nikon TE2000-E Eclipse inverted fluorescent microscope or a
Zeiss LSM 510-UV confocal microscope. Co-localization anal-
ysis was performed using associated Zeiss software package,
analyzing 30 cells under each condition.
Cell Fractionation—Procedures for permeabilization and
subnuclear extraction were described previously (33). In brief,
cells in one 15-cm plate were washed once in PBS, harvested by
scraping, and centrifuged for 5 min to pellet. The soluble frac-
tion was extracted by suspending the cells in 1 ml of low salt
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buffer (10 mM Hepes, pH 7.4, 10 mM KCl, and 50 g/ml digito-
nin) containing protease and phosphatase inhibitors (2 g/ml
leupeptin, 1 g/ml pepstatin, 1 g/ml aprotinin, 1 mM phenyl-
methylsulfonyl fluoride, and 1 mM Na3VO4) for 15 min at 4 °C.
Permeabilized nuclei were recovered by centrifugation at 2000
rpm for 5 min at 4 °C. The supernatant was termed the soluble
fraction. The nuclei were washed two additional times in the
same buffer. After wash, the nuclei were resuspended in 200 l
of low salt buffer containing 30 units of DNase I (RNase free;
Roche Diagnostics) for 15 min at room temperature and an
additional 15 min at 37 °C and then pelleted again. The super-
natant was set aside. The pellet was extracted once again with
extraction buffer (1% Triton X-100, 50 mM Hepes, pH 7.4, 150
mM NaCl, and 30 mM Na4P2O710H2O, 10 mM NaF, and 1 mM
EDTA) containing protease and phosphatase inhibitors for 15
min at 4 °C. Supernatant was collected at 14,000 rpm in a micro-
centrifuge for 10min andpooledwith the low salt bufferDNase
1 supernatant to form the chromatin fraction. Cellular fractions
were analyzed by immunoblot.
FANCD2 siRNA Knockdown—HeLa cells were grown to 60%
confluency in DMEM with 10% FBS. 60 nM FANCD2 siRNA
pool (Dharmacon, siGENOME SMARTpool) and nontargeting
control siRNA (Dharmacon, Lafayette, CO) were transfected in
HeLa cells using X-tremeGENE siRNA transfection reagent
(Roche Diagnostics) according to the manufacturer’s instruc-
tions. Soluble and chromatin fractions were made from cells
72 h after transfection and analyzed by Western blot.
RESULTS
FANCJ Binds to FANCD2—Previous data have shown that
FANCD2 monoubiquitination occurs normally in the absence
of FANCJ, leading to speculation that FANCJ acts downstream
of FANCD2 in the FA pathway (7, 9, 34). To examine the rela-
tionship of FANCD2 and FANCJ in the pathway, we wanted to
test for the interaction between FANCJ and FANCD2.We first
prepared whole cell extracts from FA-D2 mutant PD20 cells
containing empty pMMP vector or pMMP vector with cDNA
for either wild type FANCD2 or the monoubiquitination
mutant FANCD2(K561R), treated or not with 0.5 M MMC.
We immunoprecipitated the extracts with anti-FANCJ anti-
body. Subsequent immunoblotting against FANCD2 showed
that FANCD2 co-precipitated with FANCJ in both the wild
type and monoubiquitination mutant cell extracts (Fig. 1A).
Interestingly, uponMMC treatment, the amount of co-precip-
itated FANCD2was reduced in the wild type cells, whereas that
in the monoubiquitination mutant was unchanged (Fig. 1A,
lanes 1–4). The co-precipitation of FANCJ with FANCD2 was
confirmed by using Flag antibody in Flag-FANCD2-containing
cells (Fig. 1B). To rule out the possibility that DNA may play a
role in co-precipitation of FANCJ with FANCD2, we also
treated cell lysates with DNase I before performing immuno-
precipitation. No significant difference was observed between
IPswith orwithoutDNase 1 treatment (Fig. 1B). Reduced inter-
action between FANCD2 and FANCJ upon MMC treatment
was also confirmed (Fig. 1B, lane 3 versus lane 4).
The FA core complex contains FANCL, which has an E3
motif and is thought to be the putative ubiquitin ligase for
FANCD2. To test the dependence of the interaction upon
the FA core complex, we prepared similar extracts from
FA-A mutant (GM6914) and corrected cells. Anti-FANCJ
(Fig. 1C) immunoprecipitationwas performed on extracts from
untreated and MMC-treated cells. In both mutant and cor-
rected cells, the FANCJ-FANCD2 interaction was preserved,
but only in corrected cells was the DNA damage dependent
decrease seen (Fig. 1C, lane 5 versus lane 6), consistent with the
data in Fig. 1A showing this decrease only in cells with wild type
FANCD2. The interaction of FANCD2 and FANCJ was also
detected in HeLa cells along with the DNA damage-inducible
decrease (Fig. 1C, lane 1 versus lane 2), suggesting that the
interaction is not an artifact of overexpression. Monoubiquiti-
nation does not occur in core complexmutants or the FANCD2
(K561R) mutant, in which FANCD2-FANCJ interaction is
static, thus indicating that monoubiquitination of FANCD2 is
necessary for the induced dissociation of the interaction. How-
ever,monoubiquitination of FANCD2 is not sufficient for com-
plete dissociation of the interaction, because both forms of
FANCD2 can be co-precipitated by FANCJ (Fig. 1, A and C).
Confirmation of the interaction between FANCJ and FANCD2
was further provided by size exclusion chromatography of cell
protein extracts and by confocal immunofluorescence micros-
copy. Both FANCJ and FANCD2 co-fractionated in a protein
complex of 669 Da in extracts from PD20  Flag-FANCD2
cells (Fig. 1D, fractions 21–27), and immunoprecipitation with
these fractions showed that FANCJ can be pulled down by
FANCD2 (Fig. 1D). The confocal immunofluorescencemicros-
copy showed that untreated cells had significantly higher mean
co-localization (40%) than the MMC-treated cells (25%) (Fig.
1E), in agreementwith immunoprecipitation data (Fig. 1,A–C).
To ascertain whether FANCD2 and FANCJ interact directly,
we purified baculovirally generated FANCD2 and Flag-FANCJ
proteins, which were then incubated together in vitro. Immuno-
precipitation was then performed using anti-Flag agarose beads.
The beads were then washed and treated with SDS to elute pro-
teins, and samples of the supernatant, wash, and eluate were
loaded on a gel. Immunoblotting revealed that Flag-FANCJ co-
precipitated FANCD2 (Fig. 1F, lane 8), suggesting that these pro-
teins interact directly and do so in the absence of DNA.
Because FANCJ interacts with FANCD2, we tested whether
FANCJ interacts with the FA core complex. To that end, we
examined the interaction of FANCJ with the FA-core complex
protein, FANCA. Immunoprecipitation of whole cell extract
made from GM6914 FA-A cells corrected with FLAG-FANCA
did not show that FANCJ and FANCA co-precipitated under
our experimental condition, even though the interactions of
FANCJ andMLH1 or FANCA and FANCGwere observed (Fig.
1G) as shown in previous publications (35, 36).
FANCD2 Is Required for Proper Chromatin Localization of
FANCJ and BRCA1—Because FANCJ binds to bothmonoubiq-
uitinated and nonubiquitinated FANCD2 and FANCJ was
thought downstream of FANCD2, we explored the functional
significance of this interaction by studying its impact on FANCJ
chromatin loading. Extracts from FANCD2 mutant and cor-
rected cells, treated or not with MMC, were assayed by immu-
noblotting to examine chromatin loading of FANCJ. As
expected, FANCD2 localized to chromatin in a DNA damage
dependentmanner (Fig. 2A, lane 2 versus lanes 5 and 8). FANCJ
FANCJ and FANCD2 Regulate Each Other
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was also loaded onto chromatin in a DNA damage-dependent
fashion in wild type cells. However, FANCJ was loaded onto
chromatin in FA-D2mutant cells expressing no FANCD2 con-
stitutively and under DNA damage conditions (Fig. 2A, lanes 1,
4, and 7), whereas expression of FANCD2 (K561R)mutant pro-
tein interfered with FANCJ chromatin localization even under
DNA damaging conditions (Fig. 2A, lanes 3, 6, and 9). Because
FANCJ and BRCA1 are known to functionally interact and
BRCA1 foci formation is dependent on FANCJ (37), we assayed
BRCA1 and found it to show a similar pattern of chromatin
localization as FANCJ. The difference of FANCJ and BRCA1
chromatin localization was not due to the change of protein
levels, because the level of FANCJ and BRCA1 were similar in
all these three lines with or without MMC treatment (Fig. 2, B
and C). These data suggest that monoubiquitinated FANCD2 is
required for regulated FANCJ chromatin localization because of
its diminished interaction with FANCJ and because nonmono-
ubiquitinated FANCD2 acts as a negative regulatory factor in
sequestering FANCJ from chromatin under non-DNA damage
conditions. Mutant, nonmonoubiquitinatable FANCD2 thus
constitutively sequesters FANCJ, preventing FANCJ chromatin
localization.
Knockdown of FANCD2 Results in Aberrant FANCJ and
BRCA1 Localization—To confirm the behavior of FANCJ in a
FANCD2-negative background, we transfected pooled siRNA
oligonucleotides directed against FANCD2 inHeLa cells, which
resulted in diminished FANCD2 expression (Fig. 3A, lanes 3, 4,
7, and 8). Immunoblotting for FANCJ and BRCA1 demon-
strated an increase in the chromatin localization of both pro-
teins in the FANCD2-depleted cells under non-DNA damage
conditions, further suggesting that FANCD2 acts as a negative
regulator for chromatin localization for both proteins (Fig. 3B,
FIGURE 1. FANCJ interactswith FANCD2. A, anti-FANCJ immunoprecipitation followed by immunoblotting for FANCJ and FANCD2was performed onwhole
cell extracts derived from FA-D2mutant (PD20) cells transduced with empty vector, wild type FANCD2, or FANCD2 (K561R) ubiquitinationmutant. FANCJ and
FANCD2 interacted in a manner that decreased upon MMC treatment. B, anti-Flag immunoprecipitation and immunoblotting were performed on whole cell
extracts derived fromFA-D2mutant (PD20) cells transducedwithwild type Flag-FANCD2. Cell extracts were treatedwith orwithout DNase I for 15min at room
temperature and then 15min at 37 °C before being subjected to immunoprecipitation assay. C, FA-Amutant (GM6914) and corrected cells (FANCA) extracts
were prepared, and anti-FANCJ immunoprecipitation and immunoblotting were performed. Endogenous FANCJ and FANCD2 interacted, even in the core
complexmutant, but only in the corrected cells did the interaction diminish afterMMC treatment. The immunoprecipitation inHeLa cells also showed that the
endogenous proteins interacted. D, gel filtration of PD20  Flag-FANCD2 cell extracts was performed, and the resulting fractions were immunoblotted for
FANCD2andFANCJ. Bothproteins partially co-fractionated. The fractions containing FANCD2 (fractions 21–27)were combinedand subjected to Flag-FANCD2
immunoprecipitation and FANCJ immunoblot. E, confocal immunofluorescencemicroscopy shows FANCJ and FANCD2 co-localization in the absence of DNA
damage by MMC. Images were obtained using 400magnification. F, in vitro expressed FANCD2 was incubated with Flag-FANCJ, and immunoprecipitation
was performedwith Flag beads. The supernatant (S), wash (W), and SDS eluate (E) were subjected to immunoblotting. Controls (Lanes 1 and 2) indicate FANCJ
and FANCD2 proteins alone. G, whole cell extracts of FA-A patient-derived cells (GM6914) and corrected cells (GM6914 FLAG-FANCA) cells were immunopre-
cipitatedas indicated. FANCGandMLH1wereusedaspositive controls for FANCAandFANCJ interactionproteins, respectively.No interactionbetweenFANCA
andFANCJwasdetected. Thequantificationof the immunoblotwas carriedoutbyusing ImageJmethod. Themeanvalues of eachbandare shown. ctr, control;
IP, immunoprecipitation.
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lane 1 versus lane 3). The levels of FANCJ andBRCA1 in soluble
fraction were not significantly changed (Fig. 3C). Decreased
mobility of FANCJ was evident and consistent with FANCJ
becoming phosphorylated upon DNA damage.
FANCD2 and FANCJ Chromatin Localization Is Impaired in
FA-A and FA-C Core Complex Mutants—Because nonmono-
ubiquitinated FANCD2 sequesters FANCJ away from chroma-
tin, we tested FANCJ localization in FA core complex mutants.
In both FA-A and FA-C mutant cells that express nonmono-
ubiquitinated FANCD2, which fails to localize to chromatin,
decreased FANCJ chromatin localization was observed (Fig. 4,
A and B). This is in contrast to the FANCD2 deletion mutant
FA-D2 cell line (Fig. 2A), in which there was no FANCD2
expression (Fig. 4, lanes 1 and 2 versus lanes 3 and 4 and lanes 5
and 6 versus lanes 7 and 8). These data are consistent with those
displayed in Fig. 2A inwhich the FANCD2 (K561R)mutant that
fails to become monoubiquitinated sequestered FANCJ away
from chromatin, even under DNA damage conditions.
FANCJ Regulates FANCD2 Focus Formation—Conversely,
we wanted to understand whether FANCJ was required for
FANCD2 localization to chromatin.We first examined the role
of FANCJ in FANCD2 focus formation by immunofluorescence
FIGURE 2. FANCD2 is required for proper chromatin localizationof FANCJ andBRCA1.A, FA-D2mutant cells and those transducedwithwild type FANCD2
or FANCD2 (K561R) mutant were treated with the indicated dose of MMC, and chromatin extracts were prepared. Immunoblotting revealed that FANCJ was
constitutively present on chromatin in FA-D2  vector mutant expressing no FANCD2 but not present in FA-D2  FANCD2 (K561R). FANCJ chromatin
localization was inducible in wild type FANCD2-containing cells. BRCA1 followed the same pattern. B, whole cell extracts were prepared and analyzed by
immunoblotting to demonstrate that similar amounts of FANCJ were present in each and that FANCD2(K561R) was expressed, even though not present in
chromatin in A. C, whole cell extracts were similarly prepared and analyzed by immunoblot to demonstrate similar amounts of BRCA1 present in each.
FIGURE 3. Knockdown of FANCD2 results in aberrant FANCJ and BRCA1 localization. A, HeLa cells were transfected with pooled siRNA directed against
FANCD2 or luciferase (control). Cells were treated or not with MMC, and extracts were prepared. Immunoblot revealed knockdown of FANCD2 expression
(lanes 3 and 4) accompanied diminished chromatin localization (lanes 7 and 8). B, FANCJ and BRCA1 immunoblotting of extracts from A showed increased
localization of both FANCJ and BRCA1 upon FANCD2 knockdown. C, FANCJ and BRCA1 immunoblotting of soluble fraction showed similar levels of both
proteins in control or FANCD2 knockdown cells.
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microscopy studies of FANCD2 upon DNA damage, using
EUFA30 FA-J mutant and corrected. Cells were seeded onto
chamber slides and allowed to recover for 24 h and then treated
with 0.5 M MMC overnight. Following staining for FANCD2,
the cells were examined by immunofluorescencemicroscopy (Fig.
5A). Corrected FA-J cells displayed an increase in FANCD2 focus
formation after MMC treatment. Although some foci were still
detectable in mutant cells, counts of 100 cells among FA-J
mutant and corrected cells demonstrated significantly more
corrected cells with FANCD2 foci (Fig. 5B).
FANCJ Regulates FANCD2 and BRCA1 Chromatin Loading—
Because FANCD2 foci formation is associated with inducible
localization to chromatin, we next prepared chromatin or
whole cell extracts from FA-J mutant and corrected cells
treated or not with MMC to determine the effect of FANCJ on
FANCD2 chromatin localization. Immunoblotting against
FANCD2 revealed increasedMMC-induced FANCD2 localiza-
tion to chromatin only in the corrected cells (Fig. 6A, lanes 5
and 6). A similar pattern was seen with FANCI, the binding
partner of FANCD2,which is alsomonoubiquitinated. A blot of
whole cell extracts showed that FANCD2 was normally
monoubiquitinated, as expected, in the FA-J mutant and cor-
rected cells (Fig. 6B). Also as expected,MMC-induced chroma-
tin localization of BRCA1 was reduced in the FA-J mutant cells
(Fig. 6C). Again no significant difference in BRCA1 levels was
observed in whole cell extracts between FA-J mutant and cor-
rected cells (Fig. 6D).
DISCUSSION
We describe the interaction of FANCJ with FANCD2 and
characterize the dependence of each on the eventual chromatin
localization of the respective protein. We observe that
FIGURE 4. FANCD2andFANCJ chromatin localization is impaired in FA-A andFA-C core complexmutants.A and B, FA-Amutant (GM6914) and corrected
cells (FANCA) (A) and FA-C mutant (HSC536) and corrected (FANCC) (B) were treated or not with MMC and subjected to obtain chromatin extraction.
Immunoblotting revealed that only corrected cells showed the full amounts of FANCD2 and FANCJ chromatin localization after DNA damage.
FIGURE 5. FANCJ regulates FANCD2 focus formation. A, FA-J mutant and corrected (FANCJ) cells were plated and subjected to MMC treatment and then
analyzed by immunofluorescence microscopy. B, cells from A were counted, and those with greater than 20 foci per nucleus were scored as positive. The
resulting data were represented on a graph, demonstrating that induction of foci was present only in corrected FA-J cells.
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FANCD2 directly interacts with FANCJ and is a negative regu-
lator of FANCJ by virtue of the ability of nonmonoubiquiti-
nated FANCD2 to bind to FANCJ, preventing FANCJ from
localizing to chromatin. The binding of nonmonoubiquitinated
FANCD2 to FANCJ may also play a role in dissociating FANCJ
from chromatin after DNA damage is repaired. Monoubiquitina-
tionof FANCD2 is tied to eventual FANCJchromatin localization,
becausemonoubiquitinatedFANCD2has loweraffinity toFANCJ
in immunoprecipitation-immunoblotting experiments. Con-
versely, FANCJ is necessary for efficient loading of FANCD2 onto
chromatin and for FANCD2 focus formation following MMC-
induced DNA damage. Our model in Fig. 7 suggests that acti-
vation of FANCD2 via monoubiquitination, and thus eventual
localization to chromatin, is a multistep process. In this model,
FANCJ is necessary for FANCD2 to localize to chromatin after
FANCD2 monoubiquitination, thus explaining the co-precipi-
tation of both forms of FANCD2 by FANCJ in the pre-DNA
damage state.
FANCJ was originally postulated to act downstream of
FANCD2 in the FA/BRCA DNA repair pathway, because mono-
ubiquitination of FANCD2 occurs in the absence of FANCJ (38).
We propose that FANCJ function is not distinctly downstream
of FANCD2 but is cooperative with FANCD2. Monoubiquiti-
nation of FANCD2 can be uncoupled from its loading onto
chromatin and from repair focus formation, supporting previ-
ous findings that monoubiquitination of FANCD2 is necessary
but not sufficient for chromatin loading (39). Some detectable
FANCD2 foci and chromatin localizationwas seen even in FA-J
mutant cells, but it is markedly diminished in comparison with
wild type or corrected cells. Residual FANCJ protein or mutant
protein with partial function in the mutant cells may account
for this.
Nonmonoubiquitinated FANCD2 binds to FANCJ without
DNA damage, suggesting that FANCJ may sequester non-
monoubiquitinated FANCD2 in the predamage state, perhaps
in a preparatory or staging complex that facilitates rapid acti-
vation. This idea is supported by chromatography showing that
FANCJ and FANCD2 are both found in a 669-kDa complex.
Others have not previously shown this interaction, a fact that
may be accounted for by formation of different complexes con-
taining additional proteins that block epitopes specific to
FIGURE 6. FANCJ regulates FANCD2 and BRCA1 chromatin loading. A, FA-J mutant and corrected cells were treated with the indicated dose of MMC, and
chromatin extracts were prepared. Immunoblotting demonstrated that FANCD2 and FANCI loading onto chromatin was DNA damage-inducible. B, immuno-
blotting ofwhole extracts fromAdemonstrated that FANCD2monoubiquitinationwas induced in bothmutant and corrected FA-J cells.C, immunoblotting of
chromatin extracts from mutant and corrected cells demonstrated inducible localization of BRCA1 in corrected cells. D, immunoblotting of whole extracts
demonstrated that BRCA1 protein levels were similar in both mutant and corrected FA-J cells.
FIGURE 7. Model of FANCD2 and FANCJ. FANCD2 binds FANCJ. After
monoubiquitination and phosphorylation of FANCD2 and FANCJ both are
loaded onto chromatin. Without ubiquitination, FANCD2 and FANCJ remain
unbound to chromatin (shown by expression of the FANCD2(K561) mutant
but also seen in FA core complex mutants). FANCD2 can be monoubiquiti-
nated by core complex in the absence of FANCJ. However, it does not load
onto chromatin. In the absence of FANCD2, FANCJ can load onto chromatin.
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immunoprecipitating antibodies, analysis of conditions under
which FANCJ-FANCD2 interaction is diminished, or different
types of lysate preparation with respect to detergent (27).
The findings reported here contrast with those reported by
the Andreassen group (29). Close examination of the data pre-
sented in that paper in fact demonstrate some foci induction
and chromatin localization of FANCD2 in FA-J mutant cells,
contrary to the paper’s overall conclusion. Our work, on the
other hand, demonstrates an almost a complete lack of
FANCD2 foci formation and chromatin localization or induc-
tion. Technical differences may account for this because our
chromatin fractionation technique yields protein fractions con-
taining only monoubiquitinated FANCD2 as opposed to both
isoforms seen in the aforementioned paper (25, 29). In addition,
our co-immunoprecipitation data are consistent with co-local-
ization predamage and lack of co-localization by confocal
microscopy (Fig. 1E). It has long been hypothesized that FANCJ
functions downstream of FANCD2 monoubiquitination (38),
but the demonstration that FANCD2 regulates FANCJ chro-
matin localization provides a mechanism how FANCD2 con-
trols “downstream” FANCJ in the FA pathway. The model also
predicts that patients withmutations in core complex proteins,
representing the bulk of FA individuals, exhibit suboptimal
chromatin localization of FANCJ because of the association of
nonmonoubiquitinated FANCD2 with FANCJ.
FANCJ and FANCD2 are members of DNA repair protein
complexes that may include members such as BRCA1/2,
H2AX, and others. In particular, BRCA1 has been identified as
binding to and regulatingmonoubiquitinated FANCD2 (20, 40)
and histone H2AX (41). H2AX plays an important role in
retaining DNA damage proteins, such as BRCA1, on chroma-
tin. We observe that H2AX signaling is not impaired in FA-D2
mutant cells, suggesting that upstream activation events in FA
mutant cells appear to be intact (data not shown). FANCD2
focus formation during DNA damage is dependent upon
FANCJ (Fig. 5A), similar to how BRCA1 also binds to FANCJ
(42) to facilitate BRCA1 participation in repair focus formation
(37) and DNA repair (42). However, the interaction between
BRCA1 and FANCJ appears to be ubiquitous and independent
of DNA damage (37). FANCJ is also known to function inde-
pendently of BRCA1 in the chickenDT-40 cell system in aman-
ner that implicates it in the FA pathway (24). We show that the
association of BRCA1 and FANCJ is lower in the comple-
mented FA-D2 cells compared with mutant cells (Fig. 2A).
Lower MMC concentrations may result in differential stimula-
tion of such association or localization. These combined data
suggest a possible three-way interaction between FANCJ,
BRCA1, and FANCD2. The regulation of BRCA1 chromatin
localization may be multifactorial, because RAP80 forms a
complex with BRCA1 but not FANCJ and directs BRCA1 chro-
matin localization (43, 44).
Whereas the DNA helicase activity of FANCJ has been dem-
onstrated in vitro (45), this activity has yet to be shown in cells,
and the possibility remains that the helicase activity of FANCJ
serves to dissociate protein fromDNA, similar to the yeast heli-
case Srs2 (46, 47). FANCJ has also been demonstrated to
unwind guanine quadruplex structures (G4-DNA) that can
form in tracts of guanines, and a FA-J patient-derived mutant
FANCJ protein is unable to unwind these structures in vitro (48,
49). It has been speculated that certain interstrand cross-links
may preferentially form in these quadruplex structures and that
FANCJ is required for their resolution. Thus, regardless of the
precisemechanism, FANCJmay prepare DNAdamage sites for
the chromatin recruitment of DNA repair factors, such as
BRCA1 andmonoubiquitinated FANCD2. Consistent with this
premise was the demonstration that FANCJ functionally inter-
acts with TopBP1, a protein critical for the control of the DNA
replication checkpoint (50). The FANCJ-TopBP1 interaction
was shown to promote chromatin loading of RPA, a require-
ment for the activation of the apical checkpoint kinase ATR.
Therefore, FANCJ is important for responding to various forms
of replication stress and has a critical role early in DNA repli-
cation checkpoint control (51). Given these data, we postulate
that FANCJ plays a pivotal role in a regulatory pathway that
leads to FANCD2 and BRCA1 participation in replication-as-
sociated DNA damage repair.
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